# Chardan Capital

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/chardan-capital
Canonical HTML page: https://getbiobrief.com/entity/chardan-capital

## Recent coverage (1 stories)

### PVLA Drops 12.4% on Thin Volume: Biotech Risk or 45% Upside Play?
2026-08-12 12:09:27 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Full story: https://getbiobrief.com/story/pvla-shares-down-12-4-biotech-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.